Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
RFVIIIFc and rFIXFc provide effective haemostasis during orthopaedic surgery in patients with haemophilia A and B, with a favourable safety profile. Further multicentre studies are warranted to confirm these results and refine perioperative management guidelines.
Authors
- Enrica Cristini
- Lisa Pieri (ORCID: https://orcid.org/0000-0003-1812-8072)
- Christian Carulli (ORCID: https://orcid.org/0000-0002-0845-7940)
- Jacopo Acquati Lozej (ORCID: https://orcid.org/0000-0002-2615-1048)
- Sara Arcudi (ORCID: https://orcid.org/0000-0001-5743-9098)
- Simona Maria Siboni (ORCID: https://orcid.org/0000-0002-8456-7519)
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Luigi Piero Solimeno (ORCID: https://orcid.org/0000-0002-4130-3601)
- Roberta Gualtierotti (ORCID: https://orcid.org/0000-0001-6465-7624)
- Alessandro Ciavarella (ORCID: https://orcid.org/0000-0003-2297-5231)
- Emanuele Guido (ORCID: https://orcid.org/0009-0009-8073-0284)
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Florence (IT)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1111/hae.70141
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Milano
- Dipartimenti di Eccellenza
- European Commission
- Ministero della Salute
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Swedish Orphan Biovitrum
- Third Health Programme